The US Food and Drug Administration has approved a new indication for the Novartis drug Exjade (deferasirox) to treat patients aged 10 years and older who have chronic iron overload resulting from a genetic blood disorder. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
